BioNTech 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- BioNTech reported third-quarter 2026 revenue of 1.3 billion euros, compared with 1.5 billion euros in the prior-year quarter, mainly reflecting lower market demand for its COVID-19 vaccine; revenue included 613 million from its global strategic partnership with VMS.
- Adjusted R&D expenses were 579 million euros, compared with 479 million euros in the prior-year quarter, reflecting greater investment in prioritized IO and ADC programs, partly offset by lower spending outside strategic focus; IFRS R&D expenses were 748 million euros.
- Adjusted and IFRS SG&A expenses were 179 million, compared with 149 million in the prior-year quarter, mainly due to late-stage program prelaunch activities, commercial buildup, and operational initiatives.
- For the nine months ended in 2026, revenue was 1.5 billion compared with 2 billion in the prior-year period; adjusted R&D expenses were 1.6 billion compared with 1.5 billion, and adjusted SG&A expenses were 527 million compared with 407 million.
- BioNTech had 16.2 billion in cash, cash equivalents and security investments at the end of the third quarter and had repurchased approximately 5 million shares through September 30th under its share buyback program.
- In the non-pivotal initial part of its global phase 3 trial, Guttustuberk showed median overall survival of 18.5 months versus 10 months with docetaxel, with a hazard ratio of 0.56 and a 44% reduction in the risk of death; median follow-up was 25.4 months.
- In a phase one two trial, pumitamib plus LCD showed a 92% overall response rate in first-line small cell lung cancer, a 76% objective response rate in second line, and a 52% objective response rate in third line and later across 71 patients; the combination's ILD rate was 2.9%.
- In first-line metastatic triple-negative breast cancer, pumitamib plus a drop-through targeted ADC showed a confirmed objective response rate of 76.7% and a disease control rate of 96.7% in 30 patients.
- The phase two trial of autogen savumaran as adjuvant monotherapy in ctDNA positive stage two high-risk or stage three colorectal cancer was discontinued after an independent data safety monitoring board identified a numerical imbalance in overall survival between treatment arms; no new safety signals were identified.
- The first prespecified interim analysis of the BNT113 phase two trial did not meet its first dual primary endpoint of progression-free survival; the trial continues as planned to assess overall survival, following the independent data monitoring committee's recommendation.
- A global phase three trial of TPAM in HR positive HER2 low metastatic breast cancer met its primary endpoint, showing a statistically significant yet modest improvement in progression-free survival; overall survival data were not mature at the interim analysis.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to BioNTech's third quarter 2026 earnings call. I will now hand the call over to Doug Maffei, Vice President of Investor Relations.
Please go ahead. Thank you, operator.
Good morning and good afternoon, everyone. Thank you for joining BioNTech's third quarter 2026 earnings call. As a reminder, the slides we will use during this call and the corresponding press release can be found in the investor section of our website. Please also note, we will refer to both IFRS and adjusted non-IFRS financials. Our earnings release materials include a reconciliation of the adjusted results to the most directly comparable measures based on IFRS accounting standards. On the next slide, you will see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings with the U.S. Securities and Exchange Commission, or SEC. Forward-looking statements on this call are subject to significant risks and uncertainties and speak only as of the date of this conference call. We undertake no obligation to update or revise any of these statements.
On slide 3, you can find the agenda for today's call. I am joined by the following members of BioNTech's management team: Ugur Sahin, Chief Executive Officer and Co-founder, Özlem Türeci, Chief Medical Officer and Co-founder, and Ramón Zapata, Chief Financial Officer. Also available for the Q&A portion of the call is Annemarie Hanekamp, Chief Commercial Officer. With this, I will hand the call over to Ugur.
Thank you, Doug, and warm welcome to everyone joining us today. We have made good progress against our strategic milestones set out for 2026, reflecting our continued commitment to advancing our pipeline. First, we are accelerating the late-stage development of our oncology assets. At the World Conference on Lung Cancer in September, we presented updated overall survival data for gotistobart from the non-pivotal stage of our global phase III trial in patients with squamous non-small cell lung cancer who progressed on prior checkpoint inhibitor treatment. gotistobart nearly doubled median overall survival compared to standard of care chemotherapy. This is a setting where chemotherapy has remained the standard of care for more than a decade, and with gotistobart, we aim to provide a chemotherapy-free monotherapy for patients who progressed after first-line therapy. We are encouraged by the data, and the pivotal stage of the trial is ongoing.
Second, our combination therapy strategy continues to gain momentum. We recently entered into a clinical trial collaboration and supply agreement with Gilead to evaluate pumitamig in combination with their TROP2-directed antibody drug conjugate as first-line treatment for patients with metastatic PD-L1 low or negative triple-negative breast cancer. If approved by regulators, this would be the first phase III trial of pumitamig in combination with an antibody drug conjugate, and an important milestone in advancing our combination therapy strategy towards registration. Third, we continue our shift from a platform-centric to a tumor-centric clinical development approach in cancers with the greatest unmet medical need. At World Conference on Lung Cancer, we presented the first global combination data for any anti-PD-L1 VEGF bispecific immunomodulator and an ADC in lung cancer.
This combination of pumitamig and LSD demonstrated encouraging early efficacy and manageable safety profile in small cell lung cancer, across lines of treatment, including activity in first-line patients. These data are the signal-seeking evidence we set out to generate this year. The observed clinical responses are encouraging and speak to the potential of novel combinations in lifting survival curves. These data we have seen support our phase III registration and planning for pumitamig in combination with LSD. Looking ahead, BioNTech is well-positioned for the next phase of growth. With a growing pipeline of potentially registrational trials, strong partnerships, and financial strength, we are on track to become a diversified multi-product company by 2030. Our late-stage development program includes multiple pivotal trials with readouts to 2030 and beyond, spanning multiple tumor types and different lines of treatment.
As we announced last quarter, Guido Oelkers will take office as CEO by 1st February at latest. I am confident that he will bring in his valuable experience to continue advancing BioNTech's unique and strong pipeline. Management and supervisory board members have been actively engaged in supporting a seamless transition. We have built BioNTech from a startup into a global biopharmaceutical company with a strong foundation across next-generation immunomodulators, ADCs, and mRNA. We have also established a distinguished combination therapy strategy in oncology. At the heart of our work is a shared purpose: advancing medical innovation to improve patient lives. Our employees have been instrumental in bringing this purpose to life with their expertise, dedication, and commitment. It is their collective contribution that helps turn scientific discovery into meaningful progress for humanity and better outcomes for patients. We see significant potential in BioNTech.
As this will be my last earnings call, I would like to thank the many exceptional and dedicated BioNTech team members and leaders, the management and the supervisory board, our founding partners, shareholders, and collaborators. I would also like to thank the patients, investigators, and other healthcare professionals who have been contributing to our trials and our colleagues in the science community. Without all these contributors, none of this would have been possible. The impact we have created together to break through innovation for science, medicine, and patients is something I will look back on with deep gratitude. While we hand over the operational responsibility to our successors, Özlem and I will continue to follow BioNTech as founding shareholders. With this, I will hand over to Özlem.
Thank you, Ugur. I am glad to be speaking with everyone today. Our ambition at BioNTech is to address the full continuum of cancer care by exploring the synergies of immune modulators, ADCs, and mRNA cancer immunotherapies. We have defined a tumor-type-focused strategy to address unmet medical need in disease areas where our novel combinations can extend survival for patients. In the past 2 months, we presented data at key conferences for 3 of our leading product candidates: pumitamig, gotistobart, and Alpha-D. The data validate their potential clinical benefit across key tumor types, most notably in lung cancer. I will review the data and discuss how it is supportive of the lung cancer franchise BioNTech is building. Lung cancer is an area of high medical need, and we have a broad and diverse development approach to maximize our pipeline potential.
At the core of our approach is pumitamig, a bispecific immunomodulator targeting PD-L1 and VEGF-A, being developed with our partner BMS across multiple tumor types. I will focus on non-small cell lung cancer first. We are running 4 registrational programs for pumitamig in combination with standard of care or monotherapy. In parallel to these registrational trials, we are generating novel combination data with our ADCs and our mRNA immunotherapies to inform the first wave of chemotherapy-free combination trials with registrational intent. Gotistobart is another key candidate of our non-small cell lung cancer strategy. As a reminder, gotistobart is a selective Treg-depleting antibody targeting CTLA-4, developed with OncoC4. We are advancing gotistobart through the pivotal stage of a global phase III trial in patients with metastatic squamous non-small cell lung cancer who progressed following platinum-based chemotherapy and checkpoint inhibitor treatment.
This is a setting with very few effective options and poor prognosis, where median survival with current standard of care is less than 1 year. At the World Conference on Lung Cancer, we presented updated overall survival data from the non-pivotal initial part of this trial, with a median follow-up of 25.4 months. Median overall survival was 18.5 months with gotistobart versus 10 months with docetaxel, with a hazard ratio of 0.56. Gotistobart reduced the risk of death by 44% compared with chemotherapy. The observed safety profile of gotistobart was consistent with previous findings. These results reinforce the potential of gotistobart to provide a significant overall survival benefit as a chemotherapy-free monotherapy in this large, underserved patient population. In the pivotal part of the trial designed with identical protocol inclusion and exclusion criteria to stage 1, we anticipate an interim analysis before year-end.
This serves as an early data point ahead of the next pre-planned interim analysis next year. Turning to small cell lung cancer, where we are evaluating pumitamig in combination with chemotherapy, in combination with a DLL3 T-cell engager, and in combination with Alpha-D in front and later lines. Alpha-D is our B7-H3-targeted ADC developed with DualityBio. Alpha-D's clinical profile positions it as a potentially versatile oncology asset across a wide range of solid tumors. More than 1,000 patients have now been treated with Alpha-D across over 10 tumor types, including more than 500 patients treated with Alpha-D in combination with pumitamig. This was a global dataset from our phase I/II trial of pumitamig plus Alpha-D in patients with advanced small cell and non-small cell lung cancer. This combination brings together 3 independent mechanisms of action: checkpoint inhibition, VEGF-A neutralization, and the tumor cell-targeted cytotoxic payload of Alpha-D.
In 71 patients with small cell lung cancer across 4 dose levels, the combination showed a remarkable 92% overall response rate in first line, 76% objective response rate in second line, and 52% objective response rate in third line and later. Importantly, we saw activity in patients previously treated with immunotherapy, with a 60% objective response rate, and in the small group of patients previously treated with a DLL3-targeted T-cell engager, with an encouraging 88% response rate. The safety profile was manageable and consistent with data from each agent individually, with limited overlap between pumitamig and Alpha-D-associated toxicities. No dose-limiting toxicities were observed, and the ILD rate for the combination was 2.9%. These combination data support our broader strategy of evaluating pumitamig as a potential backbone for combination regimens of complementary mechanisms.
They will help to inform the clinical development strategy to address today's unmet need and tomorrow's evolving small cell lung cancer standard of care. These data we have seen in this trial will help guide our novel combination strategy in lung cancer into potential registration, with first trials expected to begin in 2027. In triple-negative breast cancer, our pumitamig plus ADC combination strategy is now entering the pivotal stage. At ESMO Breast in May, pumitamig in combination with a TROP2-targeted ADC showed a confirmed objective response rate of 76.7% and a disease control rate of 96.7% as first-line treatment in 30 patients with metastatic triple-negative breast cancer. These data confirm that pumitamig combined with a TROP2 ADC has a manageable safety profile and warrant further investigation as first-line treatment. When we initiated ROSETTA Breast-01, chemotherapy was the only option for patients with PD-L1-negative advanced TNBC.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
18 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
